Duchenne Muscular Dystrophy (DMD) MedDRA version: 18.0 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disorders
Conditions
Interventions
Product Name: Drisapersen
Product Code: Drisapersen
Pharmaceutical Form: Solution for injection
Sponsors
BioMarin Nederland BV
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Any subject who has been previously treated with an exon 51 skipping antisense oligonucleotide (drisapersen or eteplirsen) and is not eligible for another ongoing drisapersen study. Subjects who withdrew from the previous studies due to meeting laboratory safety stopping criteria may be eligible to enroll if: a. The laboratory parameters that led to stopping have resolved; benefit of further treatment with drisapersen outweighs the risk to the individual subject; and following consultation with the Medical Monitor. 2. Subjects with DMD mutation/deletion within the dystrophin gene and correctable by drisapersen-induced DMD exon 51 skipping. 3. Male subjects age >5 with DMD in whom the investigator considers treatment with drisapersen is likely to lead to improvement or prevent worsening of the condition. 4. Continued use of glucocorticoids for a minimum of 60 days prior to study entry with a reasonable expectation that the subject will remain on glucocorticoids for the duration of this study. Changes to or cessation of glucocorticoids will be at the discretion of the investigator conducting this study in consultation with the subject/parent and Medical Monitor. 5. Willing and able to comply with all study requirements and procedures (with the exception of those assessments requiring a subject to be ambulant, for those subjects who have lost ambulation). 6. Able to give informed assent and/or consent in writing by the subject and/or parent(s)/legal guardian (according to local regulations). Are the trial subjects under 18? yes Number of subjects for this age range: 215 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 5 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Subjects who have previously been treated with drisapersen and who had a serious adverse experience or who met safety stopping criteria that remains unresolved, which in the opinion of the investigator could have been attributable to drisapersen. Once resolved, subject may be eligible to enter the study following investigator consultation with the Medical Monitor. 2. Use of anticoagulants, anti-thrombotics or antiplatelet agents within 28 days of the first re-dosing of drisapersen. Chronic use of anticoagulants, anti-thrombotics or antiplatelet agents is prohibited during the study. As needed dosing (pro re nata – PRN) may be acceptable (except for aspirin) following discussion with the Medical Monitor. 3. Participation in any investigational clinical trial within 3 months prior to start or during this study (except for other drisapersen studies). If subjects have participated in any other study within the last 6 months this should be discussed with the Medical Monitor prior to start of this study. 4. History of significant medical disorder which may confound the interpretation of safety data (e.g. current or history of renal or liver disease/impairment, history of inflammatory illness) 5. Symptomatic cardiomyopathy. If subject has a left ventricular ejection fraction <45% at start of this study, the investigator should discuss inclusion of subject in this study with the Medical Monitor. 6. A platelet count under the lower limit of normal (LLN) at start of this study. A re-test is possible at a later stage, and if within normal range, the subject may enter the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: • To evaluate the long-term efficacy of subcutaneous drisapersen at a dose of 6 mg/kg/week. • To evaluate the long-term impact on functional outcomes of continued treatment with drisapersen. • To evaluate the long-term safety and efficacy of an intermittent dosing option in those subjects unable to tolerate drisapersen 6 mg/kg/week. • To evaluate the long-term safety and efficacy of an intravenous dosing option in those subjects unable to tolerate subcutaneous administration of drisapersen. ;Primary end point(s): Study Endpoints/Assessments Safety Variables: • Incidence and severity of adverse events • Vital signs • ECG parameters • Echocardiogram • Injection Site Reactions • Safety haematology and biochemistry parameters including non-standard parameters such as coagulation parameters (in particular activated partial thromboplastin time [aPTT]), serum cystatin C, Complement Factor C3, haptoglobin, fibrinogen, high-sensitivity C-reactive protein (hsCRP) • Urinalysis (including quantitative protein and creatinine and their ratio) Efficacy Variables: Ambulant subjects • Muscle function using 6 minute walking distance (6MWD) test. • North Star Ambulatory Assessment. All subjects • Pulmonary function (forced expiratory volume in the 1st second of exhalation [FEV1], forced vital capacity [FVC]). In addition, at selected sites, Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) will be assessed. • Time to major disease milestones (e.g. loss of ambulation, night time ventilation) • Performance Upper Limb (PUL) • Patient Reported Outcome Measures (PODCI and EQ-5D-5L) • MRI (at selected centers);Main Objective: To evaluate the long-term safety and tolerability of subcutaneous or intravenous drisapersen in subjects with DMD correctable by drisapersen-induced DMD exon 51 skipping who have previously participated in an eligible study. ;Timepoint(s) of evaluation of this end point: End of study | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA | — |
Countries
Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Chile, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Norway, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Uruguay
Contacts
Public ContactEdith van Dijkman
BioMarin Nederland BV
Outcome results
None listed